RenovoRx Inc
RNXT
Company Profile
Business description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
Contact
2570 West El Camino Real
Suite 320
Mountain ViewCA94040
USAT: +1 650 284-4433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,600.90 | 95.70 | -1.10% |
| CAC 40 | 7,726.20 | 60.58 | 0.79% |
| DAX 40 | 22,653.86 | 273.67 | 1.22% |
| Dow JONES (US) | 46,212.10 | 634.63 | 1.39% |
| FTSE 100 | 9,894.15 | 24.18 | -0.24% |
| HKSE | 24,829.92 | 447.45 | 1.84% |
| NASDAQ | 21,950.34 | 302.72 | 1.40% |
| Nikkei 225 | 52,134.46 | 618.97 | 1.20% |
| NZX 50 Index | 12,701.75 | 288.24 | -2.22% |
| S&P 500 | 6,582.19 | 75.71 | 1.16% |
| S&P/ASX 200 | 8,409.90 | 94.70 | -1.11% |
| SSE Composite Index | 3,849.34 | 36.06 | 0.95% |